Boehringer Ingelheim wins trial in two Zantac lawsuits
Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused ...
BioWorld2d
MASH field still hot as Boehringer axes $870M deal with Yuhan
Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp. for dual ...
PharmExec13d
Boehringer Ingelheim Launches Trivalent Vaccine for H5 Avian Influenza
Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well ...
Endpoints News12d
Boehringer In­gel­heim wins ju­ry ver­dict in Zan­tac re­tri­al in Illi­nois
An Illinois jury ruled in favor of Boehringer Ingelheim in Zantac litigation brought by two prostate cancer patients, the ...
Ahram Online13d
Boehringer Ingelheim launches new trivalent poultry vaccine, offering protection against H5 avian influenza
With VAXXITEK® HVT+IBD+H5, Boehringer Ingelheim is expanding its proven VAXXITEK® range with a new vaccine that protects ...
Business Wire13d
CDR-Life Announces Fifth Milestone Achievement with Boehringer Ingelheim in Geographic Atrophy
ZÜRICH--(BUSINESS WIRE)--CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716 ...
Boehringer Ingelheim Launches Fast-Acting Stroke Medication In The UAE, Reducing Treatment Administration To Five Seconds
The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. <li /> Administered as a ...